Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Delivery
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 240617
Licensor grants a nonexclusive license under the Licensor Patent Rights,as defined in the Scale-Up Agreement between the parties, and Licensor Know-How to use, sell. offer for sale, and import Product in the Territory manufactured by or for Licensor under this Agreement.
Compound shall mean the compound known as levalbuterol, including any salt, ester, solvate, clathrate, or polymorph thereof.
Active Ingredient shall mean micronized levalbuterol hemitartrate.
Product shall mean a press-and-breathe inhaler containing a pressurized aerosol canister with a metered dose valve as developed under the Scale-up Agreement containing Active Ingredient, oleic acid, ethanol, and 1,1.1.2-tetratluoroethane as set forth in the Specifications and prepared in accordance with the Specifications.
IPSCIO Record ID: 203483
The Product means a press-and-breathe inhaler containing a pressurized aerosol canister with a metered dose valve filled with a formulation of the Compound that Licensee has selected having the formulation, and meeting the Specifications.
The term Licensed Product means Product containing the Compound levalbuterol tartrate. Tartrate shall mean any tartaric acid salt, including but not limited to D-tartrate, L-tartrate, and DTL tartrate. in any stoichiometry, including but not limited to levalbuterol hemitartrate.
Licensor Confidential Information means confidential information disclosed by Licensor to Licensee in the course of and pursuant to this Agreement relating to aerosol inhalation, or aerosol compositions, including the specifications and chemistry of aerosol formulations of Compound developed by Licensor or its Affiliates; metered dose inhaler devices and their specifications; the methods and techniques used by Licensor to manufacture aerosol inhalers and metered dose devices; and confidential information directly or indirectly provided by Licensor to assist Licensee to obtain a license or approval permitting the sale of Licensed Product, including clinical results for metered dose devices.
Licensor Patent Rights means all patents and patent applications that are owned or controlled by Licensor or an Affiliate thereof and that cover manufacture, use, or sale of Licensed Product, including but not limited to certain of those patents claiming benefit of priority to, or having a substantially identical disclosure as, Great Britain application GB8828477, U.S. application 442,119, and, U.S. application 92,001, and all applicable continuations, continuations-inpart, divisionals, extensions, supplemental protection certificates, utility models, reissues, and reexaminations thereof.
IPSCIO Record ID: 315809
– an exclusive license, with the right to sublicense, to research, develop, import, use, market, sell, have sold, offer for sale and otherwise commercialize the Product in the Field in the U.S., and
– a co-exclusive license, with the right to sublicense, to manufacture and have manufactured the Product for the purposes of researching, developing, importing, using, marketing, selling, having sold, offering for sale and otherwise commercializing the Product in the Field in the U.S.; and,
– a non-exclusive license, with the right to sublicense, solely and to the extent needed to conduct clinical and non-clinical development activities with respect to the Product in the Field outside the U.S.
Product shall mean the drug-device combination product that is comprised of Loxapinc delivered by the Staccato Device, which has been or is during the Term approved by the FDA in the U.S., which form of product is currently designated as Adasuve®.
Staccato Device shall mean any hand-held, fixed-dosage device for the administration of API(s), which relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of API(s) through deep lung inhalation, where the device is known as or based on, but may or may not be referred to, as the Staccato® system.
The patents relate to the Delivery of antipsychotics through an inhalation route.
